Pamapimod

Pamapimod
Identifiers
	IUPAC name 6-(2,4-difluorophenoxy)-2-(1,5-dihydroxypentan-3-ylamino)-8-methylpyrido[2,3-d]pyrimidin-7-one;
CAS Number	449811-01-2;
PubChem CID	16220188;
IUPHAR/BPS	9915;
ChemSpider	17347490;
UNII	8S2C9V11K4;
KEGG	D08963;
ChEBI	CHEBI:90685;
ChEMBL	ChEMBL1090089;
PDB ligand	FLW (PDBe, RCSB PDB);
CompTox Dashboard (EPA)	DTXSID90963312 ;
Chemical and physical data
Formula	C19H20F2N4O4
Molar mass	406.390 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CN1C2=NC(=NC=C2C=C(C1=O)OC3=C(C=C(C=C3)F)F)NC(CCO)CCO;
	InChI InChI=InChI=1S/C19H20F2N4O4/c1-25-17-11(10-22-19(24-17)23-13(4-6-26)5-7-27)8-16(18(25)28)29-15-3-2-12(20)9-14(15)21/h2-3,8-10,13,26-27H,4-7H2,1H3,(H,22,23,24); Key:JYYLVUFNAHSSFE-UHFFFAOYSA-N;

Pamapimod is an investigational drug which is being evaluated for the treatment of autoimmune diseases. It is a p38 mitogen-activated protein kinase inhibitor.^[1] It has been evaluated in a phase 2 clinical trial for the treatment of rheumatoid arthritis, but was found not to be effective.^[2]^[3] It has subsequently been investigated as a possible treatment for osteoarthritis.^[4]^[5]

Quick Facts Identifiers, CAS Number ...

See also